VIE/MRSA (VIE/MRSA)
Vienna Stock Exchange: VIE/MRSA · EUR
€3,020
-40.00 (-1.3%)· Recorded snapshot
| Market cap | 44.2B | |
|---|---|---|
| Revenue (ttm) | 49.2B | |
| Net income (ttm) | 2B | |
| EPS (ttm) | €135 | |
| P/E (trailing) | 22.3x | |
| P/E (forward) | 9.2x | |
| Dividend | €64.2 (2.13%) | |
| Volume | 8 |
Market data
Price
Recent price action with selectable time range.
Financial snapshot
- Revenue (ttm)
- 49.2B
- Net income (ttm)
- 2B
- EPS (ttm)
- €135
- P/E (trailing)
- 22.3x
- P/E (forward)
- 9.2x
- Market cap
- 44.2B
Fair-value bridge
- Current price
- €3,020
In the news
Latest news · VIE/MRSA
Recent company headlines from major financial publishers.
Valuation
- Market cap
- 44.2B
- P/E (trailing)
- 22.3x
- P/E (forward)
- 9.2x
- P/S
- 0.9x
- P/B
- 0.9x
- EV / EBITDA
- 5.2x
Profitability
- Gross margin
- 21.0%
- Operating margin
- 4.8%
- ROE
- 4.4%
- ROA
- 1.9%
- ROIC
- 4.0%
Balance sheet
- Debt / equity
- 0.31
- Current ratio
- 2.03
- Quick ratio
- 1.90
Trading
- Volume
- 8
- Dividend yield
- 2.1%
Calendar
Next earnings
Upcoming earnings date and setup when available.
Upcoming
DateLoading
Window—
EPS estimate—
Revenue estimate—
Sector percentile context
Refreshed 2026-10-29 19:55 UTC
Forward P/E9.2
P25 n/aP50 n/aP75 n/a
Trailing P/E22.3
P25 n/aP50 n/aP75 n/a
ROE4.4
P25 n/aP50 n/aP75 n/a
ROIC4
P25 n/aP50 n/aP75 n/a
Benchmarks · 1M
S&P 500+0.6%
Nasdaq Composite-2.3%
Dow Jones Industrial Average+1.9%
Russell 2000+1.8%
All VIE/MRSA indicators
Market & fundamental data
Available fields
241
Groups with data
10
Currency
USD
Showing 241 of 241 available metrics for this ticker.
Deeper analysis on VIE/MRSA
14 sections in the full report · jump straight to what you need
Forecast
Base and Bull forecast paths with report-date return framing.
Valuation
Fair-value bridge, DCF, owner earnings, and peer multiples.
Sensitivity
Cost-of-equity and terminal-growth stress table.
Risks
Kill scenarios, soft-pass flags, and downside catalysts.
Earnings
Next earnings setup and beat / inline / miss thresholds.
Position sizing
Entry, exit, conviction, and quarterly monitoring rules.
Financials
Revenue, margins, cash flow, and balance-sheet context.
Peers
Relative valuation and profitability against the cohort.
Moat
Economic-profit evidence and competitive advantage risk.
Industry cycle
Sector phase, capital cycle, and secular tailwinds.
Scorecard
Six-factor overlay and 9-category weighted scorecard.
Recommendation
Final action, action steps, opportunity, and biggest risk.
Perspectives
Growth, value, and income investor reads.
Archive
Prior published reports and rating changes.
Frequently asked questions
About this VIE/MRSA report
Is a complete VIE/MRSA research report available?
No complete published report is available for vie/MRSA (VIE/MRSA) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.